Zacks.com on MSN19h
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Business Insider2d
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...
Zacks.com on MSN4d
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Renesas Jointly Developed World-Class "8-in-1" Proof of Concept with Nidec, Delivering Advanced Integration for EV E-Axles
Renesas announced the world's first "8-in-1" proof of concept for E-Axle systems for EVs, which controls eight functions with a single MCU.